NeurAxis (NRXS) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
30 Jul, 2026Management team and governance
CEO and principal executive officer is Brian Carrico, with address and contact information provided.
CFO and principal financial/accounting officer is Timothy Henrichs.
Board includes directors Christopher Robin Brown, Bradley Mitch Watkins, Beth Keyser, Kristin Ferge, and Gilad Aharon.
Offering details and pricing
Registration statement filed as Form S-3 for a proposed public offering to commence from time to time after effectiveness.
Filing is an amendment to register additional securities and file Exhibit 23.1.
Company is a smaller reporting company and emerging growth company.
Underwriters and syndicate
Legal counsel for the offering is Lucosky Brookman LLP.
Independent registered public accounting firm is Rosenberg Rich Baker Berman, P.A.
Latest events from NeurAxis
- Q2 2026 revenue up 116% to $1.93M, gross margin 85.9%, but losses and coverage risks remain.NRXS
Q2 2026 - Medtech company registers 1.9M shares for resale by holders; no proceeds to the firm.NRXS
Registration filing - Category one CPT code, expanded coverage, and strong data position for rapid growth in GI therapies.NRXS
Planet MicroCap Showcase: VEGAS 2025 - Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets.NRXS
Lytham Partners Spring 2026 Investor Conference - Neuromodulation therapies for GI disorders drive growth with FDA clearance and strong clinical data.NRXS
Investor presentation - Q1 2026 revenue up 80% with margin gains, FDA clearances, and ongoing going concern risks.NRXS
Q1 2026 - FY2025 revenue rose 33% to $3.6M, with double-digit growth, high margins, and expanded market access.NRXS
Q4 2025 - Q3 revenue up 40%, net loss down 80%, with major insurance, FDA, and CPT milestones.NRXS
Q3 2024 - Insurance expansion and new product launches set the stage for profitability in early 2025.NRXS
Q2 2024